Quratis signs USD 1.87m clinical drug supply contract with Access to Advanced Health (UK)
For reference only, not investment advice.This is a factual summary of a company filing. It is not a recommendation to buy, sell or hold any security. Read the original filing on DART before making any decision. Full disclaimer
What was filed
Quratis disclosed a contract to supply clinical-trial pharmaceuticals to Access to Advanced Health (UK) Ltd, a vaccine technology developer.
Key facts
| Contract amount | USD 1,870,000 (KRW 2.49 billion at KRW 1,331.10/USD) |
|---|---|
| Share of recent revenue | 101.31% of 2025 separate revenue (KRW 2.46 billion) |
| Counterparty | Access to Advanced Health (UK) Ltd, a London subsidiary of the US-based AAHI, set up in 2025 |
| Term | 19 Nov 2026 to 30 Jun 2030 |
| Payment terms | No advance; paid on acceptance of five milestones (contract / technical feasibility, process development/GMP production, preliminary stability, CMC documents, stability) |
Context
Payment is tied to milestone deliverables over about three and a half years rather than paid upfront.
Original filing: DART receipt no. 20261120900789 (Korean)
Figures are taken from the filing as submitted. KRW conversions use the exchange rate stated in the filing. Filings can be corrected later; the DART version prevails.